Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03298412
• Date of registration: 12/09/2017
• Prospective Registration: Yes
• Primary sponsor: Amgen
• Public title: Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
• Scientific title: A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation.
• Date of first enrolment: May 23, 2018
• Target sample size: 10
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT03298412
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Australia, Belgium, France, Greece, Italy, Switzerland, United States

Contacts

• Name: MD
• Affiliation: Amgen

Key inclusion & exclusion criteria

Inclusion and Exclusion Criteria - Part 1

Inclusion Criteria - Part 1

- Subject has provided informed consent prior to initiation of any study-specific
activities/procedures or subject's legally acceptable representative has provided
informed consent prior to any study-specific activities/procedures being initiated
when the subject has any kind of condition that, in the opinion of the investigator,
may compromise the ability of the subject to give written informed consent.

- Age = 18 at time of informed consent

- Biopsy-proven DLBCL excluding DLBCL that represents transformation of indolent
non-Hodgkin's lymphoma (NHL) Note: Lymphoblastic Lymphoma and Burkitt Lymphoma
histology are not eligible

- Subject has = 1 characteristic feature of high-risk DLBCL:

- High-risk first complete remission (defined as interim positron emission
tomography - computed tomography (PET-CT) positive or < complete remission to
frontline chemotherapy AND achieved complete remission to platinum-containing
salvage)

- Relapse within 1 year of diagnosis

- Secondary age-adjusted international prognostic index > 1

- Partial response/partial metabolic response after minimum of 2 cycles of
platinum-containing salvage chemotherapy

- C-myc rearrangement

- aHSCT with high-dose chemotherapy following first (or later) salvage treatment.

- PET-CT negative (Deauville score = 3) 90 days (± 30 days) post aHSCT

- Available relapsed and/or diagnostic pathology formalin-fixed paraffin-embedded (FFPE)
tumor block or slide samples at the time of enrollment including the successful
identification of malignant clone sequences by the central laboratory.

- MRD plasma sample collected = 3 weeks after the post aHSCT PET-CT scan

- Eastern Cooperative Oncology Group (ECOG) performance status = 2.

- Adequate organ function determined = 3 weeks prior to enrollment defined as follows:

- Hematological:

Absolute neutrophil count (ANC) = 1.0 x 109/L Platelet count = 75 x 109/L Hemoglobin = 8
g/dL

- Renal:

Creatinine clearance = 50 mL/min Cockcroft-Gault equation

- Hepatic:

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of
normal (ULN) Total bilirubin < 2 x ULN (unless Gilbert's Disease or if liver involvement
with lymphoma)

- Subject will be available to complete all protocol-required study visits or
procedures, and/or to comply with all required study procedures to the best of the
subject's and investigator's knowledge including but not limited to:

- Completion of up to a 24-month run-in period

- Completion of all regularly scheduled study visits including blood draws for MRD
assessment, clinical disease state assessment, PET-CT scans (ie, at time of MRD
positivity or relapse), assignment to treatment with blinatumomab

- Other Inclusion criteria may apply. See "Inclusion and Exclusion criteria - Part
2".

Exclusion Criteria - Part 1

- Clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure,
paresis, aphasia,stroke, severe brain injury, dementia, Parkinson's disease,
cerebellar disease, organic brain syndrome, and psychosis

- Evidence of CNS involvement with DLBCL at disease evaluation obtained prior to
starting blinatumomab

- Current autoimmune disease or history of autoimmune disease with potential of CNS
involvement

- Prior anti-CD19 directed therapies

- Prior alloHSCT

- Received radiation = 2 weeks prior to enrollment

- Infection with human immunodeficiency virus or chronic infection with hepatitis B
virus (hepatitis B surface antigen positive) or hepatitis C virus (anti-hepatitis C
virus positive)

- History of malignancy other than DLBCL within the past 3 years with the following
exceptions:

- Malignancy treated with curative intent and with no known active disease present
for = 3 years before enrollment and felt to be at low risk for recurrence by the
treating physician

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
of disease

- Adequately treated cervical carcinoma in situ without evidence of disease

- Adequately treated breast ductal carcinoma in situ without evidence of disease

- Prostatic intraepithelial neoplasia without evidence of prostate cancer

- Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in
situ

- Subject has known hypersensitivity to immunoglobulins or any of the products or
components to be administered during dosing.

- History or evidence of any other clinically significant disorder, condition or disease
(with the exception of those outlined above) that, in the opinion of the investigator
or Amgen physician, if consulted, would pose a risk to subject safety or interfere
with the study evaluation, procedures or completion.

- Women who are pregnant or breastfeeding or planning to become pregnant or breastfeed
while receiving blinatumomab and for an additional 48 hours after the last treatment
dose of blinatumomab. (Females of child bearing potential should only be included
after a negative highly sensitive urine or serum pregnancy test.)

- Women of childbearing potential unwilling to use an acceptable method of effective
contraception while receiving blinatumomab and for an additional 48 hours after last
dose of blinatumomab. Note: The pregnancy, breastfeeding and contraceptive
requirements are specific to blinatumomab. The investigator is responsible for
providing the subject (male and female) with pregnancy and breastfeeding (female only)
avoidance requirements for other medications given during the study.

- Currently receiving treatment in another investigational device or drug study or less
than 30 days since ending treatment on another investigational device or drug study.
Other investigational procedures while participating in this study are excluded.

- Other Exclusion criteria may apply. See "Inclusion and Exclusion criteria - Part
2".

Inclusion and Exclusion Criteria - Part 2

Inclusion Criteria - Part 2

- MRD-positive assessment (by NGS analysis) at enrollment or at any time during the
run-in 1 period

- PET-CT negative (defined by Deauville criteria = 3) at run-in 2 perfor


Age minimum: 18 Years
Age maximum: 100 Years
Gender: All

Health Condition(s) or Problem(s) studied

High-risk Diffuse Large B-cell Lymphoma

Intervention(s)

Drug: Blinatumomab

Primary Outcome(s)

MRD-Negative Rate at the End of Cycle 1 [Time Frame: 12 weeks (84 days)]

Secondary Outcome(s)

Number of Participants With Treatment Emergent Adverse Events (TEAEs) [Time Frame: From first dose of study drug through 30 days after the last dose of study drug. The treatment duration for the participant who received blinatumomab was 57 days.]

Kaplan-Meier Estimate: Duration of MRD-Negative Status [Time Frame: up to 1 year from first dose of blinatumomab]

Kaplan-Meier Estimate: Overall Survival (OS) [Time Frame: up to 1 year from first dose of blinatumomab]

Kaplan-Meier Estimate: Progression-Free Survival (PFS) [Time Frame: up to 1 year from first dose of blinatumomab]

Secondary ID(s)

20150291

2016-003255-30

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 11/09/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT03298412